DailyMed vs. Drugs@FDA: which peptide drug label should you use?

01

The two databases answer different questions

Drugs@FDA includes information about drugs approved for human use by FDA’s Center for Drug Evaluation and Research. FDA describes it as a source for product information, regulatory history, the most recent FDA-approved prescribing and patient labeling, and agency review documents that evaluate safety and effectiveness.

DailyMed is maintained by the National Library of Medicine. It publishes the most recent labeling companies submit to FDA and identify as currently in use. The site makes structured product labeling available in formats such as HTML, PDF, and XML and can include prescribing, patient, carton, and container labeling.

Both can be useful in peptide research, but neither should be treated as a universal list of every healthcare product. The first task is to define the question: approval and application history, current distributed labeling, package identity, or a particular warning.

02

Why a DailyMed record does not prove approval

DailyMed includes labeling for FDA-approved prescription drugs and biologics, but it also includes additional FDA-regulated products such as certain unapproved drugs, dietary supplements, cosmetics, devices, medical foods, and animal products. NLM explicitly says products marked unapproved have not been evaluated by FDA for safety and effectiveness and their labeling is not FDA-approved.

The presence of a label, NDC, labeler, or structured product listing therefore cannot establish approval by itself. This matters for peptide websites because sellers may link a DailyMed page or copy an NDC into marketing as if database inclusion were an FDA endorsement.

For approval, identify the application in Drugs@FDA or the appropriate biologics approval database. If no matching approved application appears, do not fill the gap with a DailyMed listing, drug-listing record, certificate of analysis, or pharmacy claim.

03

Why the label versions can differ

FDA and NLM explain that DailyMed’s “in use” labeling may not be identical to the most recent FDA-approved labeling. Company-submitted current labeling can include minor annual-reportable changes or certain strengthened warnings submitted through a changes-being-effected supplement while FDA review is underway.

FDA-approved labeling in Drugs@FDA reflects labeling approved by CDER. Timing can still produce apparent gaps: after an application or supplement is approved, a company generally submits structured product labeling, which is then posted to systems such as DailyMed and FDALabel. Updates do not necessarily appear in every interface at the same moment.

A difference should be investigated, not automatically labeled an error. Record each document’s date and source, compare the changed section, and look for a supplement approval, safety communication, or labeling-change record that explains the sequence.

04

A product-matching workflow for peptide medicines

Search the exact brand and established name, then match route and dosage form. Peptide and GLP-1 medicines may have injection, oral, nasal, or other presentations, and a shared ingredient does not make the labels interchangeable. Confirm the manufacturer or labeler, strength, application number, NDC when useful, and document date.

Use Drugs@FDA to establish the application and approved labeling. Then open DailyMed for searchable current labeling, carton images, or structured fields. Compare the Indications and Usage, Warnings and Precautions, Dosage Forms and Strengths, Storage and Handling, Patient Information, and Instructions for Use that matter to the research question.

If the item is compounded, do not expect an FDA-approved application-specific label. Use the dispensing label and pharmacy records instead, and preserve the distinction between a compounded label and approved prescribing information for a commercial product.

• →Exact brand and established name
• →Manufacturer, applicant, or labeler
• →Route and dosage form
• →Strength and NDC when relevant
• →NDA, ANDA, or BLA number
• →Label date and version

05

How to audit a provider’s label-based claim

Ask the provider which product and document support the statement. A storage range copied from one brand should not be applied to an unidentified compounded vial. An indication for one application should not be extended to another route or use. A warning removed or revised in a later label should not remain presented as current without context.

Link directly to the source and quote sparingly. Summaries should retain material limits, such as the approved population, route, formulation, contraindications, and date. If a provider says “the FDA label says,” the page should identify the specific label rather than linking to a broad search screen.

For safety changes, check the current label and FDA’s safety-labeling changes database. For patient-facing instructions, confirm whether the document is FDA-approved patient labeling or a pharmacy-created handout. These sources serve different audiences and may use different language.

06

Limits and best practices

Database research cannot tell a person how to use a medicine or whether it is appropriate. Labels are product-specific professional and patient information, not individualized recommendations. Questions about a prescription, storage excursion, missed dose, adverse effect, or product substitution belong with the prescriber or pharmacist using the exact product record.

Drugs@FDA also does not cover every FDA-regulated biologic; FDA directs users to separate CBER resources for products such as vaccines, blood products, and cellular or gene therapies. DailyMed may offer broad labeling coverage, but NLM warns that it is not a complete listing of all FDA-regulated products.

The practical rule is to use both tools deliberately: Drugs@FDA for approved status and history, DailyMed for current submitted structured labeling, and the package or dispensing record to confirm which product is actually involved.